•
Top 10 Listicle
Talks about Com 250, Listicles and online news consumption
AR
Alex Rosen
Managing Partner at Spruce Street Capital LP
New York, New York
Overview
Alex Rosen is a Biotech Investor at Spruce Street Capital in New York, with a background in medicine, business, and biotechnology. With experience as a Partner at Venrock and Managing Partner at Spruce Street Capital, Rosen has a strong track record in investing in biotech companies at various stages, specializing in sectors like Pharmaceuticals and BioTech.
Work Experience
Managing Partner
2024 - Current
Board Member
2023 - 2023
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.
Raised $408,000,000.00 from Wellington Management, Access Biotechnology, Bain Capital Life Sciences, HBM Partners, Decheng Capital, HBM Healthcare Investments, Samsara BioCapital, Enavate Sciences, Venrock Healthcare Capital Partners and Altshuler Shaham.
Partner
2020 - 2023
Biotech investor
2016 - 2023
Public and private/crossover biotechnology investing
Venrock is a venture capital firm investing in technology and healthcare companies.
Board Member
2022 - 2023
IPO Sep 2023 (NASDAQ: RYZB) acquired by Bristol Myers Squibb for $4.1 billion, Dec 2023
RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.
Raised $418,000,000.00 from Soleus Capital, Ally Bridge Group, Viking Global Investors, Laurion Capital Management, Wellington Management, Sands Capital Ventures and Sofinnova Investments.
Business Development
2015 - 2015
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of innovative medicines.
Raised $15,931,980.00 from U.S. Department of Health & Human Services.
Summer Associate
2014 - 2014
McKinsey Growth Tech serves leading growth stage tech players, venture capital, and growth private equity